PA-NORDIC-PHARMA
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
LACRIFILL Canalicular Gel allows patient’s eyes to be bathed in their own natural tears. It is customized for each individual patient and provides a full fill of the canalicular system. LACRIFILL Canalicular Gel is administered through a simple in-office procedure, which is reimbursed through the existing CPT code (68761), and the results last for six months.
“It’s been so exciting to be part of the launch of LACRIFILL Canalicular Gel, an interventional dry eye treatment that helps ophthalmologists with cataract, glaucoma and refractive surgeries and all of their dry eye needs. This dry eye therapy is truly changing practice and changing lives,” said Chief Commercial Officer of Eye Care U.S., Jai Parekh, MD, MBA.
Nordic Pharma is attending Kiawah Eye 2024 in Kiawah Island, SC from May 30-June 1 to share information about LACRIFILL Canalicular Gel and take orders. "LACRIFILL Canalicular Gel is a disruptive technology that will change how ophthalmologists practice,” said Program Director for Kiawah Eye and chairperson of the LACRIFILL U.S. Medical Advisory Board, Eric D. Donnenfeld, MD. “Having Nordic Pharma onsite to discuss how LACRIFILL Canalicular Gel will optimally occlude the canalicular system to maximize tear film preservation in patients with dry eye symptoms will be incredibly beneficial for Kiawah Eye attendees.”
For more information about LACRIFILL Canalicular Gel and ordering details visit lacrifill.com.
About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health. Nordic Group has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.
Nordic Group is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
About Nordic Pharma, Inc.
Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Nordic Group /Nordic Pharma’s business developments and the implementation of Nordic Group /Nordic Pharma’s strategic initiatives. Because these statements reflect Nordic Group /Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Nordic Group /Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Nordic Group /Nordic Pharma, and other factors that could affect Nordic Group /Nordic Pharma’s business and financial performance. Nordic Group /Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529287049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VeriSilicon Launches the Industry-Leading Automotive-Grade Intelligent Driving SoC Design Platform29.4.2025 02:00:00 CEST | Press release
Providing one-stop custom service from chip design and verification to automotive-grade certification VeriSilicon (688521.SH) recently announced that its automotive-grade high-performance intelligent driving system-on-chip (SoC) design platform has been verified and successfully implemented in customer projects. Leveraging VeriSilicon’s Silicon Platform as a Service (SiPaaS) business model, this platform provides robust technical support for high-performance computing applications such as autonomous driving and advanced driver assistance systems (ADAS). VeriSilicon’s chip design process has obtained ISO 26262 automotive functional safety management system certification, enabling the company to provide global customers with one-stop custom service for their automotive chips that meet functional safety requirements. Combined with its extensive portfolio of automotive-grade IPs and complete intelligent driving software platform, VeriSilicon offers end-to-end support from chip design and v
IFF Pharma Solutions to Showcase Portfolio at Excipient World 202528.4.2025 23:00:00 CEST | Press release
Sustainability Expert Will Share Key Insights on Industry-Leading Solutions for Improving Environmental Impact IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, will showcase its sustainable solutions at Excipient World 2025. The team will feature sustainable innovations, controlled-release formulations, and nitrosamine risk mitigation solutions at booth 205 from May 13-14, Gaylord National Resort and Convention Center, National Harbor, Maryland, USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428283122/en/ “At IFF Pharma Solutions, we believe sustainability is not just a responsibility but an opportunity to innovate and inspire,” said Dr. Anne Adden, global strategic marketing director for sustainability and dietary supplements. “We are committed to creating solutions that not only meet the needs of today but also pave the way for a healthier, more sustainable future. Our team of problem-solve
Winka Dubbeldam Appointed Director and CEO of SCI-Arc28.4.2025 20:50:00 CEST | Press release
The Southern California Institute of Architecture (SCI-Arc) is thrilled to share that Prof. Winka Dubbeldam has been appointed as the next Director and Chief Executive Officer of SCI-Arc. A globally recognized Dutch architect, educator, and leader in design innovation, Winka will officially assume the role on September 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428994100/en/ Winka Dubbeldam Winka brings more than three decades of experience to the forefront of architectural practice and education. She is a full Professor of Architecture and served as Chair at the University of Pennsylvania Stuart Weitzman School of Design for ten years (2013–2023). Previously she initiated and directed the Post-Professional Architecture program for ten years (2003–2013), providing international students with innovative design skills, cutting-edge theoretical and technological knowledge necessary for a productive and innovativ
NIQ announces global data collaboration with The Trade Desk to enhance audience targeting28.4.2025 19:37:00 CEST | Press release
The Trade Desk is the first global technology platform to integrate new-to-market audiences NIQ, a leading consumer intelligence company, today announced a strategic global collaboration with The Trade Desk, a global leader in advertising technology. The collaboration will integrate NIQ's consumer intelligence and global insights on shopping behaviors into The Trade Desk’s platform, supporting marketers to plan and activate ad campaigns more accurately. These new-to-market audiences, now available on The Trade Desk's media buying platform, will enable advertisers to reach their desired audiences in global markets, with effectiveness and precision. "Our collaboration with The Trade Desk represents a significant step forward in our mission to provide actionable insights across the advertising industry, at a global scale," said Joshua Pisano, Global Head of Product, Media at NIQ. "By integrating NIQ’s advanced audiences into The Trade Desk’s leading data marketplace, we are empowering adv
Actus Nutrition Acquires Protein Facility from Foremost Farms USA28.4.2025 19:30:00 CEST | Press release
Deal includes exclusive long-term whey protein supply agreement Actus Nutrition (“Actus”), a leading vertically-integrated nutritional ingredients manufacturer and portfolio company of Butterfly Equity (“Butterfly”), today finalized an agreement to purchase a 99,000 sq. ft. processing facility from Foremost Farms USA (“Foremost Farms”). The facility, located in Sparta, WI, currently manufactures whey protein products, which Actus will continue producing at the location. As part of the deal, Actus and Foremost Farms will begin a long-term exclusive, network wide whey protein partnership supporting growth for both organizations. Actus plans to invest significant capital into the facility to increase capacity and expand its capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428226854/en/ Sparta, WI Facility “We’ll be able to hit the ground running because we can plug the Sparta facility into our existing manufactur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom